Volume 28, Number 3—March 2022
Research
Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January–May 2021, Aragon, Spain
Figure 2
References
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. DOIPubMedGoogle Scholar
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15. DOIPubMedGoogle Scholar
- Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. [Erratum in: Lancet. 2021;397:880]. Lancet. 2021;397:881–91. DOIPubMedGoogle Scholar
- Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al.; ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201. DOIPubMedGoogle Scholar
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al.; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81. DOIPubMedGoogle Scholar
- Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35–45. DOIPubMedGoogle Scholar
- Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al.; 2019nCoV-501 Study Group. 2019nCoV-501 Study Group. 2019nCoV-501 Study Group. 2019nCoV-501 Study Group. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1899–909. DOIPubMedGoogle Scholar
- Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–23. DOIPubMedGoogle Scholar
- Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–29. DOIPubMedGoogle Scholar
- McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6:74. DOIPubMedGoogle Scholar
- Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397:1646–57. DOIPubMedGoogle Scholar
- Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al.; SIREN Study Group. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725–35. DOIPubMedGoogle Scholar
- Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. [Erratum in Lancet Infect Dis. 2021;21:e208]. Lancet Infect Dis. 2021;21:1539–48. DOIPubMedGoogle Scholar
- Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. DOIPubMedGoogle Scholar
- Johns Hopkins University. Coronavirus resource center. [cited 2021 Aug 1] https://coronavirus.jhu.edu/map.html
- Government of Aragon (Spain). Aragon population register. Population pyramids [in Spanish]. [cited 2021 Aug 1] https://www.aragon.es/-/piramides-de-poblacion.-aragon
- Aragon Department of Health. Aragonese COVID-19 epidemiological report [in Spanish], Zaragoza, Spain [cited 2021 Jul 31] https://datacovid.salud.aragon.es/covid
- García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines (Basel). 2021;9:433. DOIPubMedGoogle Scholar
- European Medicines Agency. COVID-19 vaccines authorized: vaccines authorised in the European Union (EU) to prevent COVID-19, following evaluation by the European Medicines Agency (EMA) [cited 2021 Jun 9]. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised
- Interterritorial Board of the Spanish National Health System. COVID-19 vaccination strategy in Spain, 8th update [in Spanish]. 2021 Jun 22 [cited 2021 Aug 1]. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion8_EstrategiaVacunacion.pdf
- Aragon Department of Health. Action plan for COVID-19 vaccination in Aragon, updated 2021 May 3 [in Spanish] [cited 2021 Aug 1]. https://www.aragon.es/documents/20127/1650151/Plan_Operativo_Vacunacion_Covid19_Aragon_20210503.pdf
- Aragon Department of Health. Aragon weekly epidemiologic bulletin, week 20 (2021 May 17–23) [in Spanish] [cited 2021 Aug 1] https://www.aragon.es/documents/20127/1650151/BEsA_202021.pdf
- Aragon Department of Health. Aragon weekly epidemiologic bulletin, week 29 (2021 July 19–25) [in Spanish] [cited 2021 Aug 1] https://www.aragon.es/documents/20127/1650151/BEsA_292021.pdf
- World Health Organization. Public health surveillance for COVID-19: interim guidance. 2020 Dec 16 [cited 2021 Aug 1]. https://www.who.int/publications/i/item/who-2019-nCoV-surveillanceguidance-2020.8
- Spanish Directorate-General of Public Health, Spanish Department of Health. Strategy for early detection, surveillance and control of COVID-19, updated 2021 Jul 23 [in Spanish] [cited 2021 Aug 1] https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf
- Aragon Department of Health. General procedure for COVID-19 healthcare in Aragon, updated 2021 Jun 29 [in Spanish] [cited 2021 Aug 1]. https://www.aragon.es/documents/20127/1650151/20210629_Procedimiento_COVID_19_Aragon.pdf
- Bianchi FP, Germinario CA, Migliore G, Vimercati L, Martinelli A, Lobifaro A, et al.; Control Room Working Group. BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report. J Infect Dis. 2021;224:431–4. DOIPubMedGoogle Scholar
- Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495–500. DOIPubMedGoogle Scholar
- Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2021;
ciab438 ; Epub ahead of print. DOIPubMedGoogle Scholar - Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al.; Working Group for the Study of COVID-19 in Navarra. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26:
2100438 . DOIPubMedGoogle Scholar - Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol. 2020;11:1817. DOIPubMedGoogle Scholar
- Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52:737–41. DOIPubMedGoogle Scholar
Page created: December 14, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.